PRE MARKET: PHARM.AS Pharming EURONEXT €1.69 23 Jan 2026: +11.33%, 51.61M vol, momentum
PHARM.AS stock opened the pre-market session sharply higher at €1.69, up 11.33% on 51,612,443 shares traded as of this update. The move pushes price to the day high and year high, well above the 50-day average of €1.4566 and the 200-day average of €1.1407. Volume is more than three times the average, signalling unusually strong interest ahead of upcoming catalysts. We review what is driving the most active trading on EURONEXT and how valuation, technicals, and model forecasts map to near-term targets.
PHARM.AS stock price and volume snapshot
Price stands at €1.69, with a one-day change of +€0.17 or +11.33%. The session range is €1.55–€1.69 and the 52-week range is €0.66–€1.69. Market capitalisation is €1,177,403,124.00 and shares outstanding are 696,688,239.
Trading volume is 51,612,443, versus an average volume of 16,190,305 (relVolume 3.19). The outsized liquidity explains why PHARM.AS is among the most active pre-market stocks on EURONEXT today.
Why PHARM.AS stock is most active: news and catalysts
The stock shows heavy activity ahead of a scheduled earnings announcement on 12 Mar 2026 and ongoing development news around Ruconest and gene-therapy collaborations. Elevated volume can reflect position adjustments by funds ahead of results or headline-driven flows.
For context on market commentary, see recent coverage on Nasdaq and analyst notes on Seeking Alpha source source. Large volume spikes often precede volatility around clinical or commercial updates in biotech names.
PHARM.AS stock financials and valuation snapshot
Key fundamentals: EPS -0.01, trailing PE -169.00 (negative due to small loss), price-to-sales 3.82, and price-to-book 5.02. Free cash flow yield is 3.81% and current ratio is 3.16, signalling short-term liquidity strength. Debt-to-equity is 0.49 and net debt to EBITDA is approximately -0.03, implying a modest net cash position on an EV basis.
Revenue per share TTM is 0.54 and operating cash flow per share TTM is 0.08. These metrics point to improving cash generation, but valuation multiples remain elevated versus larger healthcare peers.
Technical picture for PHARM.AS stock
Momentum indicators show short-term strength. RSI is 71.76 (overbought) and CCI is 301.75, while MACD histogram is small positive (MACD 0.03, signal 0.02). Bollinger band middle is €1.45 with upper band at €1.55. The stock trades above both the 50-day (€1.4566) and 200-day (€1.1407) averages.
Short-term risk: overbought signals increase pullback probability. Positive: strong OBV 198,863,450 and MFI 75.61 suggest buyers are in control during this volume surge.
Analyst view, Meyka grade and model forecast for PHARM.AS stock
Third-party sentiment is mixed; recent firm ratings include conservative recommendations in parts of the market. Importantly, Meyka AI rates PHARM.AS with a score out of 100: 64.08 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a yearly price of €1.93 and a 3-year target of €3.02. Against the current price €1.69, the one-year implied upside is +14.06% and the three-year upside is +78.67%. Forecasts are model-based projections and not guarantees. For deeper metrics and a live scorecard visit our Meyka page Meyka PHARM.AS stock page.
Risks and opportunities for PHARM.AS stock
Opportunities: steady Ruconest sales, successful clinical readouts (leniolisib, rhC1INH), and partnerships (Novartis, Orchard) could drive revenue and re-rate multiples. The company shows improving cash flow and a healthy current ratio.
Risks: biotech binary events, trial setbacks, and thin analyst coverage create volatility. Valuation metrics (high P/S and P/B) signal limited margin for error. Monitor upcoming earnings and clinical milestones closely.
Final Thoughts
PHARM.AS stock is the most active pre-market name on EURONEXT today after a +11.33% gap to €1.69 on 51,612,443 shares. The volume surge and price above both the 50- and 200-day averages suggest short-term momentum. Technical indicators are overbought, raising the chance of a near-term pullback, while fundamentals show improving cash flow and a solid current ratio of 3.16. Meyka AI’s forecast model projects €1.93 in 12 months, an implied upside of +14.06% from today’s price, and a three-year target of €3.02 (+78.67%). These projections are model-based and not guarantees; they should be weighed against binary clinical and commercial risks. Traders focused on most-active names should watch pre-earnings positioning, follow volume trends, and set clear stop levels given elevated volatility.
FAQs
What is driving the PHARM.AS stock rally pre-market?
The rally is driven by heavy volume of 51.61M shares and positioning ahead of a 12 Mar 2026 earnings release plus clinical and partnership updates. High relative volume suggests institutional flows and speculative trading.
How does Meyka AI rate PHARM.AS stock?
Meyka AI rates PHARM.AS with a score out of 100: 64.08 | Grade: B | Suggestion: HOLD. The grade factors in benchmark comparison, sector performance, growth and analyst consensus.
What price targets and forecast exist for PHARM.AS stock?
Meyka AI’s model projects €1.93 in one year (+14.06%) and €3.02 in three years (+78.67%). These are model-based projections and not guarantees.
What are the main risks for PHARM.AS stock traders?
Key risks include clinical trial setbacks, disappointing earnings, and valuation compression. Overbought technicals increase pullback risk during high-volume trading days.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
